Skip to content
DataLookout
Menu

NCT06131450

A Study of BL-M07D1 in Patients With Recurrent or Metastatic Gynecologic Malignancies

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 6 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 32 words Show 4 more changesShow less
    • Enrollment increased: 138 → 158 participants
    • Primary completion date: Dec 2026 to Jan 2027
    • Secondary endpoints: details revised at 5 of 9 entries
    • Study title shortened, about 1 word
  2. Notable Primary completion date: Dec 2025 to Dec 2026
    • Study completion date: Dec 2025 to Dec 2027
    v7
  3. Notable Enrollment target: 58 to 138v6
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 2024 to Feb 29, 2024
    • Site details revised
    v4
  5. Notable Start date: Dec 2023 to Feb 2024
    • Collaborators expanded, about 5 words
    v3
  6. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Phase Ib: Recommended Phase II Dose (RP2D)
Timeframe: Up to approximately 24 months
Phase II: Objective Response Rate (ORR)
Timeframe: Up to approximately 24 months

Secondary (9)

Treatment-Emergent Adverse Event (TEAE)
Phase Ib: Objective Response Rate (ORR)
Disease Control Rate (DCR)
Duration of Response (DOR)
Progression-free Survival (PFS)
Show 4 moreShow less
Cmax
Tmax
Ctrough
ADA (anti-drug antibody)

Arms and interventions

BL-M07D1Experimental

Participants receive BL-M07D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Drugs: BL-M07D1

Sites

1 site in 1 country

  • Cancer Hospital, Chinese Academy of Medical SciencesBeijing, Beijing Municipality, China